Charlotte's Web minority-interest DeFloria gets FDA clearance for Phase 2 autism trial

Charlotte's Web Holdings, Inc.

FDA cleared DeFloria's IND to proceed with Phase 2 trial of AJA001 Oral Solution for autism spectrum disorder symptoms.
AJA001 uses Charlotte's Web proprietary full-spectrum CBD hemp extract from patented cultivars.
Phase 2 will assess safety/tolerability/efficacy in adolescents and adults with ASD.
DeFloria is a collaboration between Charlotte's Web (minority stake) and Ajna BioSciences PBC.
CEO cites milestone in moving hemp genetics from consumer wellness to regulated medical sector.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.